BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20156954)

  • 1. Summarizing historical information on controls in clinical trials.
    Neuenschwander B; Capkun-Niggli G; Branson M; Spiegelhalter DJ
    Clin Trials; 2010 Feb; 7(1):5-18. PubMed ID: 20156954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using historical control information for the design and analysis of clinical trials with overdispersed count data.
    Gsteiger S; Neuenschwander B; Mercier F; Schmidli H
    Stat Med; 2013 Sep; 32(21):3609-22. PubMed ID: 23722585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
    Hupf B; Bunn V; Lin J; Dong C
    Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust meta-analytic-predictive priors in clinical trials with historical control information.
    Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
    Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size calculation for clinical trials analyzed with the meta-analytic-predictive approach.
    Qi H; Rizopoulos D; van Rosmalen J
    Res Synth Methods; 2023 May; 14(3):396-413. PubMed ID: 36625478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive adjustment of the randomization ratio using historical control data.
    Hobbs BP; Carlin BP; Sargent DJ
    Clin Trials; 2013; 10(3):430-40. PubMed ID: 23690095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel power prior approach for borrowing historical control data in clinical trials.
    Shi Y; Li W; Liu GF
    Stat Methods Med Res; 2023 Mar; 32(3):493-508. PubMed ID: 36601652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison Between a Meta-analytic Approach and Power Prior Approach to Using Historical Control Information in Clinical Trials With Binary Endpoints.
    Isogawa N; Takeda K; Maruo K; Daimon T
    Ther Innov Regul Sci; 2020 May; 54(3):559-570. PubMed ID: 33301135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictively consistent prior effective sample sizes.
    Neuenschwander B; Weber S; Schmidli H; O'Hagan A
    Biometrics; 2020 Jun; 76(2):578-587. PubMed ID: 32142163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified power prior with multiple historical trials for binary endpoints.
    Banbeta A; van Rosmalen J; Dejardin D; Lesaffre E
    Stat Med; 2019 Mar; 38(7):1147-1169. PubMed ID: 30360016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing shared internal control arms and historical information in small-sized platform clinical trials.
    Jiao F; Tu W; Jimenez S; Crentsil V; Chen YF
    J Biopharm Stat; 2019; 29(5):845-859. PubMed ID: 31462131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size re-estimation incorporating prior information on a nuisance parameter.
    Mütze T; Schmidli H; Friede T
    Pharm Stat; 2018 Mar; 17(2):126-143. PubMed ID: 29181869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian borrowing from historical control data in a vaccine efficacy trial.
    Peng L; Jin J; Chambonneau L; Zhao X; Zhang J
    Pharm Stat; 2023; 22(5):815-835. PubMed ID: 37226586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic use of historical controls in clinical trials for rare disease research: A re-evaluation of the MILES trial.
    Harun N; Gupta N; McCormack FX; Macaluso M
    Clin Trials; 2023 Jun; 20(3):223-234. PubMed ID: 36927115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using horseshoe prior for incorporating multiple historical control data in randomized controlled trials.
    Ohigashi T; Maruo K; Sozu T; Gosho M
    Stat Methods Med Res; 2022 Jul; 31(7):1392-1404. PubMed ID: 35379046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian Phase II optimization for time-to-event data based on historical information.
    Bertsche A; Fleischer F; Beyersmann J; Nehmiz G
    Stat Methods Med Res; 2019 Apr; 28(4):1272-1289. PubMed ID: 29284369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
    Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
    BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propensity-score-based meta-analytic predictive prior for incorporating real-world and historical data.
    Liu M; Bunn V; Hupf B; Lin J; Lin J
    Stat Med; 2021 Sep; 40(22):4794-4808. PubMed ID: 34126656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Including historical data in the analysis of clinical trials: Is it worth the effort?
    van Rosmalen J; Dejardin D; van Norden Y; Löwenberg B; Lesaffre E
    Stat Methods Med Res; 2018 Oct; 27(10):3167-3182. PubMed ID: 28322129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating historical control information in ANCOVA models using the meta-analytic-predictive approach.
    Qi H; Rizopoulos D; van Rosmalen J
    Res Synth Methods; 2022 Nov; 13(6):681-696. PubMed ID: 35439840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.